WebDec 17, 2024 · Prior treatment with 5-FU or gemcitabine administered as a radiation sensitizer during and up to 4 weeks after radiation therapy is allowed. If a subject received prior neoadjuvant or adjuvant chemotherapy, tumor recurrence must have occurred more than 6 months after completing the last dose of chemotherapy. WebSep 21, 2016 · Purpose We conducted a phase I trial of gemcitabine given twice weekly with concurrent radiotherapy in patients with muscle-invasive bladder cancer. Patients and Methods Eligible patients underwent maximal transurethral resection of their bladder tumors followed by twice-weekly infusion of gemcitabine with 2 Gy/d concurrent radiotherapy to …
Cetuximab, Radiotherapy and Twice Weekly Gemcitabine to Treat ...
WebMar 14, 2024 · The main objective of the clinical trial is to determine if modified FOLFIRINOX (mFFX) alternated with biweekly Gemcitabine plus Nab-Paclitaxel (mGnabP) administered as a combined, front-line therapy will result in longer time to treatment failure (TTF) compared to the current standard of care with mFFX alone in treatment-naive … WebFeb 20, 2008 · A Phase II Trial of Biweekly Gemcitabine, Paclitaxel, and Avastin as Frontline Therapy for Metastatic Breast Cancer: Study Start Date : November 2006: ... Patients must have >14 days delay between the conclusion of any radiation and the start of gemcitabine, provided the acute effects of radiation treatment have resolved. ... fmc cork
Gemcitabine Combinations in Metastatic Breast Cancer (MBC), …
WebMar 15, 2014 · The gemcitabine recommended dose of 400 mg/m 2 /week was then evaluated in a phase 2 study that was unfortunately prematurely closed because of low … Web- Gemcitabine:2000 to 3000mg/m2 IV (in the vein) on days 1 and 15 every 28 days over 30-60 minutes. - Paclitaxel: 150 mg/m2 IV(in the vein)on days 1 and 15 every 28 days over … WebFeb 20, 2008 · Purpose: Gemcitabine is effective in the treatment of pancreatic cancer and is a potent radiosensitizer. This study assessed safety and efficacy of full-dose gemcitabine administered before and during concurrent three-dimensional conformal radiation (3D-CRT) in patients with nonmetastatic pancreatic cancer. Patients and methods: f m c corp